/5+44PFZ@F06_-]KO@J37Z9
SYSTEM PROCESSING...
/5+44PFZ@F06_-]KO@J37Z9
SYSTEM PROCESSING...
Posted: 2025-05-10 21:22:31 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-05-10 21:22:41 UTC
Verified By
Rollup News
Alex Kintu, a Ugandan scientist at Gilead Sciences, is spearheading research on lenacapavir, a twice-yearly injectable for HIV prevention, which has demonstrated 100% efficacy in trials, marking a significant advancement for high-risk adolescent girls and young women, particularly in regions like South Africa and Uganda.
Lenacapavir shows 100% efficacy in HIV prevention.
Potential transformation of HIV prevention strategies worldwide.
Addresses the HIV epidemic's impact on underserved populations.
Addressing the HIV epidemic in high-risk regions.
Developing innovative prevention methods for underserved populations.
Securing approval for lenacapavir to transform HIV prevention strategies.